Lansoprazole and Hepatocellular damage - a phase IV clinical study of FDA data

Summary:

Hepatocellular damage is reported as a side effect among people who take Lansoprazole (lansoprazole), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Lisinopril, and have High blood pressure.

The phase IV clinical study analyzes which people have Hepatocellular damage when taking Lansoprazole. It is created by eHealthMe based on reports of 128,069 people who have side effects when taking Lansoprazole from the FDA, and is updated regularly.

What is Lansoprazole?

Lansoprazole has active ingredients of lansoprazole. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 129,663 Lansoprazole users. Check the latest studies of Lansoprazole.

What is Hepatocellular damage?

Hepatocellular damage (liver damage) is found to be associated with 508 drugs and 610 conditions by eHealthMe. Check the latest studies of Hepatocellular damage.

On Aug, 08, 2026

128,069 people reported to have side effects when taking Lansoprazole.
Among them, 62 people (0.05%) have Hepatocellular damage.

Could Lansoprazole cause Hepatocellular damage?

Among these 62 people:

How long have people been on Lansoprazole when they have Hepatocellular damage? *

What is the gender of people who have Hepatocellular damage when taking Lansoprazole? *

female: 61.29 %
male: 38.71 %

What is the age of people who have Hepatocellular damage when taking Lansoprazole? *

What are other drugs people take besides Lansoprazole? *

What are other side effects people have besides Hepatocellular damage? *

Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 14 people, 22.58%
Hepatic Failure (liver failure): 13 people, 20.97%
Haematemesis (vomiting of blood): 10 people, 16.13%
Hypovolaemia (a decreased volume of circulating blood in the body): 10 people, 16.13%
Labile Blood Pressure (wildly fluctuating blood pressure): 10 people, 16.13%
Hepatic Infarction (particular area of the liver has lost its blood supply and died): 9 people, 14.52%
Acute Kidney Failure: 9 people, 14.52%
Hepatorenal Syndrome (renal failure in patients with advanced chronic liver disease): 9 people, 14.52%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 9 people, 14.52%
Liver Function Tests Nos Abnormal: 8 people, 12.90%

What are the existing conditions these people have? *

High Blood Pressure: 12 people, 19.35%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 11 people, 17.74%
High Blood Cholesterol: 9 people, 14.52%
Asthma: 7 people, 11.29%
Muscle Spasms (muscle contraction): 6 people, 9.68%
Anaesthesia: 6 people, 9.68%
Pain: 5 people, 8.06%
Ankylosing Spondylitis (type of arthritis affecting the spine): 3 people, 4.84%
Juvenile Arthritis (arthritis-related condition that develops in children or teenagers): 2 people, 3.23%
Depression: 2 people, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Lansoprazole and have Hepatocellular damage?

- Check whether Hepatocellular damage is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lansoprazole:

Lansoprazole (129,663 reports)

Browse all side effects of Lansoprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatocellular damage:

Hepatocellular damage (508 drugs)

Browse all the conditions that are associated with Hepatocellular damage:

Hepatocellular damage (610 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lansoprazole (the active ingredients of Lansoprazole) and Lansoprazole (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.